1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
OmniAb, Inc.

OmniAb, Inc.

OABIW
OmniAb, Inc.US flagNASDAQ Capital Market
0.10
USD
+0.00
- -
14.48MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
18
23
35
59
34
26
19
29
Operating Margin (%)
-71.12
-110.12
-102.48
-45.11
-203.19
-282.3
-369.49
-210.63
Depreciation Expense
11
13
16
18
19
24
22
24
Net Income, GAAP
-14
-18
-27
-22
-51
-62
-65
-54
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-74.18
-75.46
-77.82
-37.8
-148.16
-235.05
-347.04
-187.59
Working Capital
- -
2
2
99
72
53
49
52
LT Debt
- -
2
13
24
22
19
16
16
Total Equity
- -
236
234
341
315
288
267
263
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-396.56
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
17
16
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
144
144
145
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
66
65
65
Cash, Cash Equivalents & STI
60
54
49
Accounts Receivable, Net
3
7
13
Inventories
- -
- -
1
Total Current Liabilities
13
16
14
Payables & Accruals
2
2
2
ST Debt
4
4
4
Deferred Revenue
2
3
3

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.32%
-7.16%
Free Cash Flow
- -
-1,326.42%
-10.88%
Net Income, GAAP
- -
38.05%
4.43%
Sales/Revenue/Turnover
- -
5.03%
-29.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
8
4
11
26
2025
4
4
2
8
19
2026
14
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Matthew W. Foehr
Full Time Employees
114
Sector
Healthcare
Industry
Biotechnology
Address
5980 Horton Street EmeryVille CA United States of America 94608
IPO Date
Sep 30, 2021
CIK
0001846253
Website
omniab.com
Similar Companies
BerGenBio ASA (BRRGF)
Eyenovia, Inc. (EYEN)
Idera Pharmaceuticals, Inc. (IDRA)
Clal Biotechnology Industries Ltd. (CBI.TA)
Vanta Bioscience Limited (VANTABIO.BO)
Protagenic Therapeutics, Inc. (PTIXW)
Business
OmniAb, Inc. (OABIW) is a biotechnology company that licenses proprietary discovery research technologies to pharmaceutical and biotech companies, as well as academic institutions, to enable the development of next-generation therapeutics through diverse antibody repertoires and advanced screening platforms. The company offers a comprehensive suite of transgenic animal platforms powered by Biological Intelligence, including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, OmniTaur, and OmnidAb for generating fully human or humanized antibodies, single-domain antibodies, and cow-inspired structures suitable for challenging targets; these support modalities such as bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, and targeted radiotherapeutics. Complementary technologies encompass OmniDeep, a suite of in silico AI and machine learning tools for discovery and optimization, alongside high-throughput single B-cell screening, computational antigen design, and specialized capabilities in ion channels and transporters. Founded in 2012 and headquartered in Emeryville, California, OmniAb operates globally, serving over 100 active partners across biopharmaceutical firms and research institutions with 399 active programs as of September 30, 2025, including 32 in clinical development or commercialization. In recent developments, the company launched the xPloration high-throughput single B-cell screening platform in 2025, featuring instruments, proprietary consumables, and software subscriptions to enhance partner efficiencies; it completed a $30 million private placement to bolster its balance sheet; and entered multiple new license agreements in 2025, including with Veraxa Biotech, Duke-NUS, University of Strathclyde, A*Star, University of Leeds, and Dana-Farber Cancer Institute. OmniAb anticipates the December 2025 launch of OmniUltra, a transgenic chicken platform producing antibodies with ultralong CDRH3s for accessing difficult binding pockets, further expanding its offerings amid 36 net program additions year-to-date through Q3 2025.